219 related articles for article (PubMed ID: 21285398)
1. Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation.
Guillet V; Gueguen N; Cartoni R; Chevrollier A; Desquiret V; Angebault C; Amati-Bonneau P; Procaccio V; Bonneau D; Martinou JC; Reynier P
FASEB J; 2011 May; 25(5):1618-27. PubMed ID: 21285398
[TBL] [Abstract][Full Text] [Related]
2. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A.
Cartoni R; Arnaud E; Médard JJ; Poirot O; Courvoisier DS; Chrast R; Martinou JC
Brain; 2010 May; 133(Pt 5):1460-9. PubMed ID: 20418531
[TBL] [Abstract][Full Text] [Related]
3. Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A.
Cartoni R; Martinou JC
Exp Neurol; 2009 Aug; 218(2):268-73. PubMed ID: 19427854
[TBL] [Abstract][Full Text] [Related]
4. The Charcot-Marie Tooth Disease Mutation R94Q in MFN2 Decreases ATP Production but Increases Mitochondrial Respiration under Conditions of Mild Oxidative Stress.
Wolf C; Zimmermann R; Thaher O; Bueno D; Wüllner V; Schäfer MKE; Albrecht P; Methner A
Cells; 2019 Oct; 8(10):. PubMed ID: 31640251
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.
Franco A; Dang X; Zhang L; Molinoff PB; Dorn GW
J Pharmacol Exp Ther; 2022 Nov; 383(2):137-148. PubMed ID: 36507849
[TBL] [Abstract][Full Text] [Related]
6. Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A.
Franco A; Dang X; Walton EK; Ho JN; Zablocka B; Ly C; Miller TM; Baloh RH; Shy ME; Yoo AS; Dorn GW
Elife; 2020 Oct; 9():. PubMed ID: 33074106
[TBL] [Abstract][Full Text] [Related]
7. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations.
Detmer SA; Chan DC
J Cell Biol; 2007 Feb; 176(4):405-14. PubMed ID: 17296794
[TBL] [Abstract][Full Text] [Related]
8. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations.
Chung KW; Kim SB; Park KD; Choi KG; Lee JH; Eun HW; Suh JS; Hwang JH; Kim WK; Seo BC; Kim SH; Son IH; Kim SM; Sunwoo IN; Choi BO
Brain; 2006 Aug; 129(Pt 8):2103-18. PubMed ID: 16835246
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the mitofusin 2 R94W mutation in a knock-in mouse model.
Strickland AV; Rebelo AP; Zhang F; Price J; Bolon B; Silva JP; Wen R; Züchner S
J Peripher Nerv Syst; 2014 Jun; 19(2):152-64. PubMed ID: 24862862
[TBL] [Abstract][Full Text] [Related]
10. MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives.
Stuppia G; Rizzo F; Riboldi G; Del Bo R; Nizzardo M; Simone C; Comi GP; Bresolin N; Corti S
J Neurol Sci; 2015 Sep; 356(1-2):7-18. PubMed ID: 26143526
[TBL] [Abstract][Full Text] [Related]
11. Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-Tooth type 2A.
Rizzo F; Bono S; Ruepp MD; Salani S; Ottoboni L; Abati E; Melzi V; Cordiglieri C; Pagliarani S; De Gioia R; Anastasia A; Taiana M; Garbellini M; Lodato S; Kunderfranco P; Cazzato D; Cartelli D; Lonati C; Bresolin N; Comi G; Nizzardo M; Corti S
Cell Mol Life Sci; 2023 Nov; 80(12):373. PubMed ID: 38007410
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic spectrum of MFN2 mutations in the Spanish population.
Casasnovas C; Banchs I; Cassereau J; Gueguen N; Chevrollier A; Martínez-Matos JA; Bonneau D; Volpini V
J Med Genet; 2010 Apr; 47(4):249-56. PubMed ID: 19889647
[TBL] [Abstract][Full Text] [Related]
13. The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system.
Pich S; Bach D; Briones P; Liesa M; Camps M; Testar X; Palacín M; Zorzano A
Hum Mol Genet; 2005 Jun; 14(11):1405-15. PubMed ID: 15829499
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations.
Amiott EA; Lott P; Soto J; Kang PB; McCaffery JM; DiMauro S; Abel ED; Flanigan KM; Lawson VH; Shaw JM
Exp Neurol; 2008 May; 211(1):115-27. PubMed ID: 18316077
[TBL] [Abstract][Full Text] [Related]
15. [Mitofusin 2 as a crucial peripheral nervous system protein and a common regulator of cell metabolism].
Kawalec M; Kotruchow K; Kochański A; Zabłocka B
Postepy Biochem; 2011; 57(2):215-21. PubMed ID: 21913423
[TBL] [Abstract][Full Text] [Related]
16. Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion.
Vielhaber S; Debska-Vielhaber G; Peeva V; Schoeler S; Kudin AP; Minin I; Schreiber S; Dengler R; Kollewe K; Zuschratter W; Kornblum C; Zsurka G; Kunz WS
Acta Neuropathol; 2013 Feb; 125(2):245-56. PubMed ID: 22926664
[TBL] [Abstract][Full Text] [Related]
17. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.
Baloh RH; Schmidt RE; Pestronk A; Milbrandt J
J Neurosci; 2007 Jan; 27(2):422-30. PubMed ID: 17215403
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease.
Loiseau D; Chevrollier A; Verny C; Guillet V; Gueguen N; Pou de Crescenzo MA; Ferré M; Malinge MC; Guichet A; Nicolas G; Amati-Bonneau P; Malthièry Y; Bonneau D; Reynier P
Ann Neurol; 2007 Apr; 61(4):315-23. PubMed ID: 17444508
[TBL] [Abstract][Full Text] [Related]
19. CMT2A-linked MFN2 mutation, T206I promotes mitochondrial hyperfusion and predisposes cells towards mitophagy.
Das R; Maity S; Das P; Kamal IM; Chakrabarti S; Chakrabarti O
Mitochondrion; 2024 Jan; 74():101825. PubMed ID: 38092249
[TBL] [Abstract][Full Text] [Related]
20. Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease.
Gentil BJ; Minotti S; Beange M; Baloh RH; Julien JP; Durham HD
FASEB J; 2012 Mar; 26(3):1194-203. PubMed ID: 22155564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
